Wroblewski B A, Garvin W H
Arch Neurol. 1985 Jul;42(7):699-700. doi: 10.1001/archneur.1985.04060070093024.
The clinical anticonvulsant efficacy of once-daily administration of phenobarbital sodium was evaluated in 29 adults with head injuries. All patients were initially well controlled, with therapeutic blood levels of phenobarbital obtained from divided dose regimens, ranging from two to four daily administrations. All therapies were then converted to once-daily administration of the total dose at bedtime. Twenty-six patients (93%) remained within normal therapeutic blood levels without any dose change. Phenobarbital can safely, and perhaps should, be administered in a once-a-day regimen, with resultant benefits of probable increased compliance and decreased daytime sedation, if administered at bedtime.
对29例头部受伤的成年人评估了每日一次服用苯巴比妥钠的临床抗惊厥疗效。所有患者最初病情得到良好控制，通过分剂量给药方案获得了苯巴比妥的治疗血药浓度，给药频率为每日2至4次。然后将所有治疗方案转换为睡前一次服用总剂量。26例患者（93%）在未改变剂量的情况下血药浓度仍保持在正常治疗范围内。如果在睡前给药，苯巴比妥可以安全地，或许也应该以每日一次的方案给药，这样可能会提高依从性并减少日间镇静作用。
